Lonza Group AG
XMUN:LO3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lonza Group AG
XMUN:LO3
|
CH |
|
F
|
flatexDEGIRO AG
SWB:FTK
|
DE |
|
W
|
Waterdrop Inc
F:717
|
CN |
|
B
|
Bertrandt AG
DUS:BDT
|
DE |
|
K
|
Kian Santang Muliatama PT Tbk
IDX:RGAS
|
ID |
|
MPH Health Care AG
F:93M1
|
DE |
|
Salesforce Inc
BMV:CRM
|
US |
|
T
|
Thai Binh Cement JSC
VN:TBX
|
VN |
|
E
|
EDP Energias de Portugal SA
DUS:EDP
|
PT |
|
S
|
Schneider Electric SE
XHAM:SND
|
FR |
|
F
|
First Graphene Ltd
OTC:FGPHF
|
AU |
|
I
|
Innospec Inc
F:OCT
|
US |
|
Thomson Reuters Corp
TSX:TRI
|
CA |
|
N
|
NOW Inc
F:11N
|
US |
|
Equinor ASA
F:DNQA
|
NO |
|
M
|
Medpal AI PLC
LSE:MPAL
|
UK |
Lonza Group AG
Lonza Group AG is a life sciences company that makes and supplies ingredients, materials, and manufacturing services used in medicines and other health products. It does not sell to ordinary consumers; instead, it works behind the scenes for drug makers, biotech companies, and healthcare customers that need help developing or producing complex products. Its business is split between custom manufacturing and specialty ingredients. Lonza helps customers develop medicines and then produce them at scale, especially harder-to-make treatments such as biologics and cell and gene therapies. It also sells products and services used in pharmaceutical research, quality control, and the production of ingredients for nutrition and personal care. Lonza makes money by charging customers for contract development, manufacturing, and related services, along with sales of specialized ingredients and materials. What makes its model different is that it sits in a critical part of the drug supply chain: customers rely on Lonza for technical know-how, tightly controlled production, and the ability to make complex products that are difficult to produce in-house.
Lonza Group AG is a life sciences company that makes and supplies ingredients, materials, and manufacturing services used in medicines and other health products. It does not sell to ordinary consumers; instead, it works behind the scenes for drug makers, biotech companies, and healthcare customers that need help developing or producing complex products.
Its business is split between custom manufacturing and specialty ingredients. Lonza helps customers develop medicines and then produce them at scale, especially harder-to-make treatments such as biologics and cell and gene therapies. It also sells products and services used in pharmaceutical research, quality control, and the production of ingredients for nutrition and personal care.
Lonza makes money by charging customers for contract development, manufacturing, and related services, along with sales of specialized ingredients and materials. What makes its model different is that it sits in a critical part of the drug supply chain: customers rely on Lonza for technical know-how, tightly controlled production, and the ability to make complex products that are difficult to produce in-house.
Q3 Performance: Lonza reported a strong Q3 across its CDMO businesses, aligning well with its full-year outlook.
2025 Guidance: The company confirms its upgraded 2025 outlook, targeting CDMO sales growth of 20%–21% at constant exchange rates and a core EBITDA margin of 30%–31%.
Vacaville Update: Vacaville is expected to deliver at the upper end of the CHF 0.5 billion sales range in 2025, with better-than-expected margins and flat sales through 2028.
Contracting Momentum: Lonza signed several significant multiyear contracts in Q3, especially for Vacaville, and sees strong ongoing customer interest.
CHI Business Carve-Out: Internal separation measures for CHI are nearing completion, with timing of the final exit to be announced when decided.
Macro & Trade: The company sees no material impact from recent U.S. tariffs and maintains a well-diversified global manufacturing footprint.
Cell & Gene & Early-Stage: Cell & Gene performance improved in H2 but remains below 2024 levels, while early-stage CDMO business remains robust with 6–9 months visibility.
Management
Dr. Wolfgang Wienand is a prominent figure in the life sciences and pharmaceutical industry, known for his leadership role at Lonza Group AG, a global supplier to the pharmaceutical, biotech, and specialty ingredients markets. Dr. Wienand joined Lonza in 2015, and over the years, he has held various executive positions within the company, including Chief Strategy Officer and Chief Executive Officer. Equipped with a comprehensive academic background, Dr. Wienand holds a Ph.D. in organic chemistry. His career spans over two decades in the life sciences sector, where he has accumulated extensive experience in corporate strategy, business development, and operations management. His leadership style is marked by a strategic and innovation-driven approach to business growth and development. At Lonza, Dr. Wienand has played a pivotal role in advancing the company's strategic direction, contributing to its focus on expanding its global footprint and enhancing its offerings in pharmaceuticals and biotech manufacturing. Under his guidance, Lonza has continued to strengthen its position as a leader in the life sciences industry. Dr. Wienand is recognized for his ability to drive transformation and foster sustainable growth through strategic partnerships and innovation, ensuring that Lonza stays at the forefront of industry advancements.
Equipped with a comprehensive academic background, Dr. Wienand holds a Ph.D. in organic chemistry. His career spans over two decades in the life sciences sector, where he has accumulated extensive experience in corporate strategy, business development, and operations management. His leadership style is marked by a strategic and innovation-driven approach to business growth and development.
At Lonza, Dr. Wienand has played a pivotal role in advancing the company's strategic direction, contributing to its focus on expanding its global footprint and enhancing its offerings in pharmaceuticals and biotech manufacturing. Under his guidance, Lonza has continued to strengthen its position as a leader in the life sciences industry.
Dr. Wienand is recognized for his ability to drive transformation and foster sustainable growth through strategic partnerships and innovation, ensuring that Lonza stays at the forefront of industry advancements.
As of the most recent information, Maria Soler Nunez is an executive at Lonza Group AG, a prominent Swiss multinational company specializing in biotechnology and pharmaceuticals. She serves as the Chief Human Resources Officer (CHRO) and is a member of the Executive Committee. Maria Soler Nunez has a strong background in human resources and has accumulated extensive experience in developing and executing HR strategies to support business goals. Her leadership involves overseeing human resources operations, driving talent management initiatives, and fostering an inclusive company culture. Prior to joining Lonza, she held various HR leadership roles in international companies, demonstrating her expertise in strategic HR management and her commitment to employee development and organizational growth. Her role at Lonza focuses on aligning the human resources function with the ambitious growth and innovation objectives of the company. For the latest and more detailed information, it would be advisable to consult Lonza Group AG's official communications or credible business sources.
Maria Soler Nunez has a strong background in human resources and has accumulated extensive experience in developing and executing HR strategies to support business goals. Her leadership involves overseeing human resources operations, driving talent management initiatives, and fostering an inclusive company culture. Prior to joining Lonza, she held various HR leadership roles in international companies, demonstrating her expertise in strategic HR management and her commitment to employee development and organizational growth. Her role at Lonza focuses on aligning the human resources function with the ambitious growth and innovation objectives of the company.
For the latest and more detailed information, it would be advisable to consult Lonza Group AG's official communications or credible business sources.
Dr. Matthias Hofmann is an accomplished executive at Lonza Group AG, a prominent global leader in supplying pharmaceutical, biotechnology, and specialty ingredients. Holding a Ph.D. in Chemistry, Dr. Hofmann has built his career through extensive experience in the chemical and pharmaceutical industries. In his capacity at Lonza, he plays a crucial role in driving the company's innovation initiatives and enhancing operational efficiencies. His leadership is characterized by a strong focus on advancing technological development and fostering strategic partnerships to promote Lonza's growth and market leadership. Throughout his career, Dr. Hofmann has been recognized for his strategic vision and ability to implement sustainable solutions in the industry.
Jean-Christophe Hyvert is a key figure at Lonza Group AG, a global leader in life sciences that enables a healthier world by supporting the health and well-being of people. Hyvert serves as the President of the Biologics and Cell & Gene division, where he plays a pivotal role in steering the company's strategic direction and operational management within these critical sectors. His responsibilities involve overseeing the development and manufacturing of biologics and cell and gene therapies, which are vital components in the modern pharmaceutical landscape. With a background rich in the life sciences industry, Jean-Christophe Hyvert brings extensive experience and expertise to his role at Lonza. He has been instrumental in driving innovation and ensuring the company's offerings align with the fast-evolving needs of the healthcare industry. Known for his leadership skills and strategic vision, Hyvert has contributed significantly to Lonza's reputation as a leader in developing complex pharmaceuticals and biotechnology products. Under his leadership, Lonza continues to expand its capabilities and global reach in biologics, enhancing its support to biotech and pharmaceutical companies in bringing new and effective therapies to market. Hyvert's influence is seen in the company's commitment to delivering high-quality services and solutions that meet regulatory standards and address global health challenges.
With a background rich in the life sciences industry, Jean-Christophe Hyvert brings extensive experience and expertise to his role at Lonza. He has been instrumental in driving innovation and ensuring the company's offerings align with the fast-evolving needs of the healthcare industry. Known for his leadership skills and strategic vision, Hyvert has contributed significantly to Lonza's reputation as a leader in developing complex pharmaceuticals and biotechnology products.
Under his leadership, Lonza continues to expand its capabilities and global reach in biologics, enhancing its support to biotech and pharmaceutical companies in bringing new and effective therapies to market. Hyvert's influence is seen in the company's commitment to delivering high-quality services and solutions that meet regulatory standards and address global health challenges.
Aurelie Dalbiez is an accomplished executive at Lonza Group AG, a leading global provider of integrated healthcare solutions. She serves as the Global Head of Communications & External Affairs. In this role, Dalbiez is responsible for managing and overseeing the communication strategies that align with Lonza's business objectives, enhancing the company's reputation, and ensuring effective stakeholder engagement. She has extensive experience in corporate communications, public affairs, and strategic planning. Dalbiez plays a crucial role in shaping the public image of Lonza, managing media relations, and fostering transparent communications across various platforms. Her leadership is instrumental in promoting Lonza's corporate values and reinforcing its commitment to innovation in the biopharmaceutical and specialty ingredients markets. Prior to her role at Lonza, Dalbiez held various positions in communication and external affairs in other prominent companies, where she developed her expertise in global communications strategies and stakeholder management. Her background showcases a deep understanding of the complexities of communicating within highly regulated industries.
She has extensive experience in corporate communications, public affairs, and strategic planning. Dalbiez plays a crucial role in shaping the public image of Lonza, managing media relations, and fostering transparent communications across various platforms. Her leadership is instrumental in promoting Lonza's corporate values and reinforcing its commitment to innovation in the biopharmaceutical and specialty ingredients markets.
Prior to her role at Lonza, Dalbiez held various positions in communication and external affairs in other prominent companies, where she developed her expertise in global communications strategies and stakeholder management. Her background showcases a deep understanding of the complexities of communicating within highly regulated industries.
